stockportfolio.pro
Royalty Pharma plc (RPRX)
Healthcare · Biotechnology · NasdaqGS
Royalty Pharma plc revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.79B | $1.81B | $2.12B | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $1.38B | $2.35B | $975.04M | $619.73M | $42.83M | $1.13B | $858.98M | $770.95M |
| Net margin | 76.8% | 129.4% | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
Source: Royalty Pharma plc SEC filings (10-K).
Explore 8 years of Royalty Pharma plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RPRX in your portfolio →
Royalty Pharma plc financial history by metric
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc — frequently asked questions
What is Royalty Pharma plc's revenue?
Royalty Pharma plc (RPRX) reported revenue of $2.38B for fiscal year 2025, up 5.1% from the prior year, according to its SEC filings.
Is Royalty Pharma plc profitable?
Yes. RPRX earned net income of $770.95M in fiscal 2025, a net margin of 32.4%.
What is RPRX's P/E ratio?
Royalty Pharma plc trades at a price-to-earnings ratio of about 28.9 based on the latest data in our nightly-refreshed cache.
How fast is Royalty Pharma plc growing?
RPRX's revenue grew at roughly 2.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Royalty Pharma plc have?
As of fiscal year 2025, RPRX carried roughly $8.95B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Royalty Pharma plc's market cap?
Royalty Pharma plc (RPRX) has a market capitalization of about $31.64B, based on the latest data in our nightly-refreshed cache.
When does Royalty Pharma plc's fiscal year end?
RPRX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Royalty Pharma plc's official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.